Viracta Therapeutics Inc

-0.25 (-5.16%)
Earnings Announcements

Viracta Therapeutics Reports Q3 Loss Per Share Of $0.40

Published: 11/10/2021 13:16 GMT
Viracta Therapeutics Inc (VIRX) - Viracta Therapeutics Reports Third Quarter 2021 Financial Results and Provides Corporate Update.
Q3 Loss per Share $0.40.
Expects to End 2021 With Over$100 Million in Cash and Cash Equivalents, Which It Expects to Sufficiently Fund Its Operations Into 2024, Excluding Additional Borrowings Under $50 Million Credit Facility.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.40

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.30

More details on our Analysts Page.